Medicare Enrolled

Dr. Alan Finkel, MD

Neurology · Durham, NC
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
6114 FAYETTEVILLE RD STE 109, Durham, NC 27713
9199424424
In practice since 2006 (19 years)
NPI: 1114098530 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Finkel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Finkel? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Finkel

Dr. Alan Finkel is a neurology specialist in Durham, NC, with 19 years of NPI registration. Based on federal Medicare data, Dr. Finkel performed 16,746 Medicare services across 289 unique beneficiaries.

Between the years covered by Open Payments, Dr. Finkel received a total of $379,602 from 55 pharmaceutical and/or device companies across 1256 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Finkel is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 6% volume in NC $379,602 industry payments

Medicare Practice Summary

Medicare Utilization ↗
16,746
Medicare services
Top 6% in NC for neurology
289
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~881 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Botox injection, per unit
An injection of onabotulinumtoxinA, a medication used to temporarily relax muscles or reduce gland activity. The dose is measured in units, with this code representing a single unit administered.
16,100 $5 $8
Psychological or neuropsychological test, first 30 minutes
Administration of psychological or neuropsychological testing for the first 30 minutes.
311 $24 $124
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
165 $68 $352
Bilateral facial and neck nerve muscle paralysis injection
Injection of a chemical agent to paralyze muscles in the face and neck on both sides.
67 $95 $420
Chemical nerve block for neck muscles
Injection of a chemical agent to paralyze specific muscles on the side of the neck, excluding the voice box.
43 $125 $373
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
37 $51 $243
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
23 $98 $492
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$379,602
Total received (2018-2024)
Avg $54,229/year across 7 years
Top 2% in NC for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
55
Companies
1,256
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$312,861 (82.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$54,923 (14.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,818 (3.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$11,555
2023
$4,480
2022
$3,376
2021
$78,124
2020
$61,832
2019
$113,256
2018
$106,979

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$10,616
PFIZER INC.
$297
Lundbeck LLC
$229
Lilly USA, LLC
$107
IDORSIA PHARMACEUTICALS US INC
$72
Teva Pharmaceuticals USA, Inc.
$62
Merz Pharmaceuticals, LLC
$49
Otsuka America Pharmaceutical, Inc.
$36
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$28
Amgen Inc.
$25
SCILEX PHARMACEUTICALS INC.
$20
Tonix Medicines, Inc.
$15
Top 3 companies account for 96.4% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$165,117
Allergan, Inc.
$73,188
Allergan Inc.
$37,130
Lilly USA, LLC
$30,731
AbbVie Inc.
$15,932
ABBVIE INC.
$13,858
Biohaven Pharmaceuticals, Inc.
$13,376
Ipsen Innovation
$9,254
Novartis Pharmaceuticals Corporation
$6,709
Teva Pharmaceuticals USA, Inc.
$5,521
Promius Pharma LLC
$1,710
Novartis Pharma AG
$1,000
Lundbeck LLC
$767
PFIZER INC.
$575
IMPEL PHARMACEUTICALS INC.
$500
Upsher-Smith Laboratories LLC
$474
UPSHER-SMITH LABORATORIES LLC
$360
Biohaven Pharmaceutical Holding Company Ltd.
$356
Avanir Pharmaceuticals, Inc.
$274
Supernus Pharmaceuticals, Inc.
$235
ARBOR PHARMACEUTICALS, INC.
$227
Bausch Health US, LLC
$203
Otsuka America Pharmaceutical, Inc.
$194
Collegium Pharmaceutical, Inc.
$189
Merz Pharmaceuticals, LLC
$188
Zyla Life Sciences
$143
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$143
Assertio Therapeutics, Inc.
$136
Impax Laboratories, Inc.
$115
Merck Sharp & Dohme Corporation
$105
Arbor Pharmaceuticals, Inc.
$93
IDORSIA PHARMACEUTICALS US INC
$86
JAZZ PHARMACEUTICALS INC.
$76
Amneal Pharmaceuticals LLC
$67
ASSERTIO THERAPEUTICS, Inc.
$59
Egalet US Inc
$57
Merck Sharp & Dohme LLC
$47
EISAI INC.
$44
Takeda Pharmaceuticals U.S.A., Inc.
$41
SCILEX PHARMACEUTICALS INC.
$39
BioDelivery Sciences International, Inc.
$35
Pernix Therapeutics Holdings, Inc.
$32
Currax Pharmaceuticals LLC
$26
Scilex Pharmaceuticals Inc.
$21
Electronic Waveform Lab, Inc.
$21
Virtus Pharmaceuticals LLC
$21
Jazz Pharmaceuticals Inc.
$19
Eisai Inc.
$16
Daiichi Sankyo Inc.
$16
Tonix Medicines, Inc.
$15
Kowa Pharmaceuticals America, Inc.
$14
Purdue Pharma L.P.
$14
MDD US Operations, LLC
$13
Zyla Life Sciences, Inc.
$12
Vertical Pharmaceuticals, LLC
$11
Top 3 companies account for 72.6% of all-time payments
Associated products mentioned in payments ›
AIMOVIG · AJOVY · AMG334A_AIMOVIG_NEUROSCIENCE · Aimovig · Amitiza · BELSOMRA · BOTOX · BOTOX - MIGRAINE · BOTOX COSMETIC · BOTOX THERAPEUTIC · BUNAVAIL 2.1 mg 30-count box · Belbuca · CAMBIA · COMIRNATY · CONTRAVE · COPAXONE · Cambia · Dayvigo · Dysport · ELYXYB - celecoxib · EMGALITY · Edarbi · Edarbyclor · GRALISE · Gralise · Horizant · INJECTAFER · LEVORPHANOL TARTRATE · METHYLPHENIDATE 72 · MIGRANAL · MYOBLOC · NUEDEXTA · NURTEC ODT · Nuedexta · PAXLOVID · QUDEXY XR Topiramate Extended Release Capsules · QULIPTA · QUVIVIQ · RELISTOR · REYVOW · SEGLENTIS · SILENOR · SPRIX · SUNOSI · SYMPROIC · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TROKENDI XR · Tosymra Sumatriptan Nasal Spray · Trintellix · Trudhesa · UBRELVY · VYEPTI · XIFAXAN · XTAMPZA · Xeomin · Xyrem · ZEMBRACE SYMTOUCH · ZOMIG · ZTLido · Zembrace · Zembrace SymTouch Sumatriptan Injection · Zipsor
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (82%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for neurology in NC.

Looking for a neurology specialist in Durham?
Compare neurologists in the Durham area by procedure volume, costs, and industry payment transparency.
Browse neurologists nearby

Geographic Context

Neurologists within 10 mi
115
Per 100K population
34.9
County median income
$79,501
Nearest hospital
UNC HOSPITALS
8.7 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Finkel is a mixed practice specialist, with above-average Medicare volume (top 6% in NC), with speaking/promotional industry engagement in the top 2% of NC peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Finkel experienced with botox injection, per unit?
Based on Medicare claims data, Dr. Finkel performed 16,100 botox injection, per unit services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Finkel receive payments from pharmaceutical companies?
Yes. Dr. Finkel received a total of $379,602 from 55 companies across 1,256 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Finkel's costs compare to other neurologists in Durham?
Dr. Finkel's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Finkel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →